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Abstract
Background: The most common causative agent for hemorrhagic fever with renal syndrome in Germany is
Puumala virus (PUUV) and a high percentage of patients with PUUV infection have gastrointestinal (GI) symptoms.
The aim of the present study was to determine the prevalence of increased lipase levels and acute pancreatitis
during nephropathia epidemica (NE) in 166 patients from Germany.
Methods: Clinical and laboratory data during the acute phase of the disease were obtained from medical reports
and files from 456 patients during acute hantavirus infection. Patients in whom serum lipase levels were determined
during acute course of the disease were included in the study.
Results: Lipase levels at the time of diagnosis were determined in 166 of the 456 NE patients (36 %). Of the 166
patients, 25 (15 %) had elevated lipase levels at the time of admission to hospital or first contact with general
practitioner/nephrologist. In total 7 patients had a threefold increased serum lipase above the normal range.
Abdominal pain was not more often present in the group of patients with elevated serum lipase compared to
the lipase-negative group (9/25 vs 58/141). Abdominal ultrasound and CT scans revealed no signs of pancreatitis
in any of the patients. Patients with elevated serum lipase had higher serum creatinine peak levels (p = 0.03)
during the course of the disease.
Conclusions: Elevated lipase levels were common in our patient cohort and might reflect a more severe form
of NE. NE does not lead to acute pancreatitis.
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Background
Pathogenic hantaviruses are able to cause disease in
humans and after inhalation of virus containing aerosols
to known syndromes may arise: haemorrhagic fever with
renal syndrome (HFRS), with the milder subtype
nephropathia epidemica (NE) and the hantavirus cardio-
pulmonary syndrome (HCPS). HFRS is endemic in large
parts of Eastern and Northern Europe and Asia, whereas
clustered outbreaks of HCPS (with case fatality rates
(up to 60 %) [1, 2]) have been reported in South and
North America [2–4] The growing list of affected coun-
tries (developing and developed countries) has led to
public health concerns, especially after the outbreak of
hantavirus infection in the Yosemite National Park in
California during the summer of 2012 and the incidence
peak in Germany in 2012 [5, 6]. In Germany, the incidence
of HFRS increased from 0.09 cases/100.000 persons in
2001 to 2.47 cases/100.000 persons in 2010 [7]. The most
common causative agent for HFRS in Germany is Puumala
virus (PUUV) [5]. PUUV causes nephropathia epidemica
(NE) [8, 9] and patients typically present with acute kidney
injury and thrombocytopenia [10, 11].
Within the prodromal phase of about 3–5 days with
flu-like symptoms (fever, headache, nausea/vomiting
and/or visual disturbances), a high percentage of pa-
tients with PUUV infection have severe gastrointestinal
(GI) symptoms, e.g. abdominal pain, nausea and vomit-
ing [9, 10, 12–16]. The clinical presentation might be
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misleading, resulting in surgery e.g. for suspected appen-
dicitis. Some studies from Asia, Albania and the United
States have reported that abdominal pain during the
acute phase of HFRS may be caused by acute pancrea-
titis [17–21]. There have been two case reports of pa-
tients with acute pancreatitis during acute HFRS (total 3
patients) from Albania [21] and Korea [20], and further
studies from Asia [17, 19] and the United States [18] re-
vealed 25 of 387 patients (6.5 %) with acute pancreatitis
during HFRS. In these studies, the acute pancreatitis rate
during the acute hantavirus infection ranged between
2.8 % and 54 %. Differential diagnosis of acute kidney
injury with signs of systemic inflammation is broad
including e.g. leptospirosis (Weil’s disease, Stuttgart
disease), sepsis, autoimmune disease, and thrombotic
microangiopathy. Recently, we could show that procalci-
tonin could not be used to exclude acute NE [22].
Therefore, laboratory testing in the emergency depart-
ment or at first contact with general practitioner/
nephrologist include mainly various laboratory values.
It is noteworthy that serum lipase has a sensitivity and
specificity for acute pancreatitis ranging from 82 to
100 % [23]. Additionally, increased levels of pancreatic
enzymes have been reported in patients with impaired
renal function even in the absence of pancreatic diseases
although lipase tended to be less frequently raised than
pancreatic enzymes [24]
To date, the prevalence of elevated lipase levels and
acute pancreatitis and its impact on the clinical course
of the disease has not been studied in a cohort of
patients with PUUV-induced NE.
The aim of the present study was to determine the
prevalence of increased lipase levels and acute pancrea-
titis during NE in 166 patients from Germany.
Methods
Patients
Between 2001 and 2012, 7476 patients with serologically
and clinically confirmed NE were reported to the Robert
Koch Institute in Berlin (Robert Koch Institute, SurvStat,
www3.rki.de/SurvStat). All patients met the national
case definition for hantavirus infection [25, 26] In co-
operation with four selected local health authorities in
southern Germany (Stuttgart, Boeblingen/Sindelfingen,
Esslingen, Reutlingen), all infected patients between
2001 and 2012 were contacted via mail requesting an
appointment in our outpatient clinic (in total, 1570
patients were serologically confirmed to have NE).
Between September 2012 and April 2013, 456 out of
the 1570 contacted patients with serologically and clinic-
ally confirmed NE were included in our study. All
patients gave written consent before participating in the
study, which was approved by the Ethics Committee of
the Ethics Commission of the State Chamber of
Medicine in Baden-Württemberg (Stuttgart) (F-2012-
046). Studies were conducted in concordance with the
Declaration of Helsinki.
Data acquisition
Acute phase of NE
Clinical and laboratory data at the time of diagnosis and
during the acute course of the disease were obtained
from medical reports and files from the 456 patients. Pa-
tients in whom lipase levels were measured during acute
course of the disease were included in the current ana-
lysis. Patients with serum lipase levels ≥ 60 U/L (normal
range < 60 U/L in our laboratory) were classified as
lipase positive, while those with serum lipase levels
< 60 U/L were classified as lipase negative. Lipase levels
were not measured routinely in our study population,
but rather at the treating physician’s discretion (certainly
in cases of suspected acute pancreatitis).
Definition of diagnosis of acute pancreatitis
The diagnosis of acute pancreatitis requires two of the
following three features: (1) abdominal pain consistent
with acute pancreatitis (acute onset of a persistent,
severe, epigastric pain often radiating to the back); (2)
serum lipase activity (or amylase activity) at least three
times greater than the upper limit of normal; and (3) char-
acteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and less
commonly magnetic resonance imaging (MRI) or
transabdominal ultrasonography [27–29].
Statistical analysis
All continuous variables were tested for normal distribu-
tion using the Kolmogorov–Smirnov test and are pre-
sented as means ± standard deviations. The median with
interquartile range is reported where the distribution
was not normal. Nonparametric tests (Fisher’s exact test,
Mann–Whitney U test) were used for statistical analysis.
Results
Lipase levels were determined in 166 of the total 456
(36 %) patients at the time of diagnosis of NE. The base-
line characteristics of the study population are shown in
Table 1. Of the 166 patients, 141 (85 %) had lipase levels
within the normal range (<60 U/L) at time of admission
to hospital or first contact with general practitioner/
nephrologist. Conversely, 25 of the 166 patients had ele-
vated lipase levels (≥60 U/L) and 28 % of these patients
had a threefold increased serum lipase above the normal
range (7 patients, Table 2). In total, 67 of the 166 pa-
tients (40 %) had abdominal pain at time of diagnosis.
The number of patients with increased lipase levels was
not significantly different between the groups with and
without abdominal pain (9/25 vs 58/141). Abdominal
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ultrasound was performed in 88 % of the patients with
elevated serum lipase, but demonstrated no signs of
acute pancreatitis. In two patients, CT scans of the abdo-
men were performed, revealing no signs of pancreatitis.
Patients with elevated serum lipase were significantly
older (p = 0.01), had higher serum creatinine levels at ad-
mission (p = 0.008), and higher serum creatinine peak
levels (p = 0.03) throughout the course of the disease.
Duration of hospital stay was not different between
both groups (p = 0.7). Neither C-reactive protein (CRP)
levels nor thrombocyte counts were different between
both groups at time of admission to hospital or first con-
tact with general practitioner/nephrologist and through-
out the course of the disease (p > 0.05). Patients with at
least threefold increased serum lipase above the normal
range had lower creatinine levels (2.5 (1.9-2.9) mg/dl vs
3.7 (1.7-6.2) mg/dl), but lower thrombocyte counts (117
(75–277) × 109/L vs 82 (59–11) × 109/L) at time of ad-
mission to hospital or first contact with general practi-
tioner/nephrologist and lower creatinine peak levels
during acute course of the disease (3.1 (2.7-4.5) mg/dl vs
5.6 (2.9-6.9) mg/dl) without reaching statistical signifi-
cance (all p > 0.5) (Table 2).
We compared baseline characteristics (e.g. symptoms,
laboratory findings, age, creatinine, CRP levels at hos-
pital admission) during the acute course of the disease
between patients in whom lipase levels had been tested
(n = 166) and those in whom lipase had not been tested
(n = 290). No statistically significant differences were ob-
served between the groups except that, in the group of
patients in whom lipase levels had been determined,
there was a higher number of patients with abdominal
pain (p = 0.02), with a lower thrombocyte count (p <
0.05), presenting with headache (p < 0.001), and in whom
Table 1 Clinical data of 166 patients in whom serum lipase was measured at time of admission to hospital or first contact with
general practitioner/nephrologist, significant p values were marked in bold
Variable Patients with normal serum lipase Patients with elevated serum lipase p
n 141 25 -
Age (years ± SD) 45.3 ± 14.2 57.7 ± 12.2 0.001
Female/male 56/85 6/19 0.798
Onset of symptoms prior to admission to hospital (days) 5.5 (3.6-7.0) 4.5 (3.8-7.3) 0.398
Duration of hospital stay (days) 7.0 (4.0-9.0) 6.5 (5.0-11.0) 0.694
Symptoms
Abdominal pain 58/141 9/25 1.000
Back-/flank pain 102/141 17/25 1.000
Headache 96/141 12/25 0.185
Visual disorders 35/141 6/25 0.566
Diarrhea 35/141 7/25 1.000
Nausea/vomiting 69/141 10/25 1.000
Laboratory findings
Thrombocytes at admission (×109/L) 105.5 (78.0-172.5) 91.0 (73.5-215.5) 0.233
Minimum thrombocyte level (×109/L) 98.0 (69.8-161.5) 91.0 (73.0-207.5) 0.167
Creatinine at admission (mg/dL [0.5-1.4]) 1.7 (1.1-3.5) 2.9 (1.6-5.1) 0.008
Creatinine peak level (mg/dL [0.5-1.4]) 2.7 (1.7-4.6) 4.6 (2.7-6.8) 0.025
CrP at admission (mg/dL [0.1-0.4]) 4.1 (2.9-7.5) 5.8 (2.5-8.5) 0.871
CrP peak level (mg/dL [0.1-0.4]) 4.8 (3.0-8.5) 5.6 (2.4-8.8) 0.792
Lactate dehydrogenase, serum 273.5 (242.0-318.0) 285.0 (239.0-374.5) 0.348
Clinical signs
Fever 123/141 21/25 0.280
Blood pressure
systolic 130.0 (119.0–140.0) 147.0 (124.8-157.8) 0.010
diastolic 80.0 (70.0–89.0) 80.0 (74.9-97.5) 0.306
Heart rate 76.5 (63.0–88.0) 80.5 (75.5-91.8) 0.471
Abdominal ultrasound 119/141 22/25 0.770
Abdominal CT scan, native 5/141 3/25 0.101
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abdominal ultrasound and CT scans had been performed
(Table 3).
Discussion
This is the first study to determine the prevalence of in-
creased lipase levels and acute pancreatitis in a large co-
hort of NE patients. At time of diagnosis, a high
percentage of patients with PUUV infection had severe
gastrointestinal symptoms, e.g. abdominal pain, nausea
and vomiting [9, 10, 12–16]. In one-third of our patient
cohort, lipase levels were tested, which underlines that
acute pancreatitis was a differential diagnosis for NE in
patients with signs of inflammation, acute kidney injury
with thrombocytopenia, and abdominal pain in a high
proportion of patients. In our patient cohort, 15 % of the
patients had elevated serum lipase levels at time of diag-
nosis and 7 patients had a threefold increased serum
lipase above the normal range. Only two of them had
abdominal pain and none of the patients had signs of
acute pancreatitis using imaging techniques (abdominal
ultrasound or CT scans). Other studies reported acute
pancreatitis rates of between 2.8 % and 54 % during the
course of acute hantavirus infection. Recently we
demonstrated PUUV antigen in the appendix of an NE
patient with severe acute kidney injury, who had under-
gone surgery because of severe abdominal pain. We in-
vestigated biopsies of the human intestine in patients
with acute PUUV infection in order to understand why
a majority of patients with NE have severe abdominal
pain [15], for which there has so far been no pathophysi-
ologic explanation. Immunohistochemical analysis re-
vealed PUUV nucleocapsid antigen in 62 % of the
analyzed biopsies, but the presence of PUUV antigen did
not correlate with the extent of abdominal complaints
[15]. Therefore, we can find no definitive explanation for
the abdominal pain. PUUV nucleocapsid antigen was lo-
cated mainly in endothelial cells of capillaries or larger
vessels in the lamina propria of the biopsies of the hu-
man intestine. We hypothesized that systemic infection
could be linked to the presence of PUUV nucleocapsid
antigen in human intestine and might explain the clin-
ical phenotype of severe gastrointestinal symptoms. At
present, the cause of the abdominal symptoms is un-
known. Involvement of the pancreas might be present in
a significant part of the patients, as described in our co-
hort with about 15 %. This of course does not represent
the sole factor of abdominal pain and there seem to be a
group of patients with subclinical increases in lipase.
In our study population, only two out of seven patients
presented with threefold increased serum lipase levels
above the normal range. Remarkably, none of these pa-
tients received pancreatitis-specific treatment and none
of the patients had an increase of lipase levels within the
course of the disease.
Regarding differential diagnosis at time of first contact
with the patient, it has to be mentioned that there is still
a discussion whether pancreatic enzymes were elevated
within threefold normal in patients with impaired kidney
function [30, 31] and most NE patients still had acute
kidney injury at time of diagnosis. Slightly elevated levels
of lipase has been reported in patients with impaired
renal function even in the absence of pancreatic diseases
[24], but it is noteworthy that the 7 patients with lipase
levels more than threefold normal in our study had less
impaired clearance as compared to the other lipase posi-
tive patients. Therefore impaired clearance may not be
the reason for the marked elevated lipase.
In these patients, elevated lipase levels should no lead
to misdiagnose acute NE, but acute pancreatitis must be
considered if enzyme levels are more than threefold nor-
mal in association with clinical manifestations.
Table 2 Clinical data of 25 patients with elevated Lipase and
acute PUUV infection, significant p values were marked in bold
Variable Patients with elevated
serum lipase within
threefold normal
Patients with lipase at
least three times greater
than the upper limit
n 18 7
Age (years ± SD) 58 ± 12.8 56 ± 11.3
Female/male 7/11 1/6
Symptoms
Abdominal pain 7/18 2/7
Back-/flank pain 13/18 4/7
Headache 9/18 3/7
Visual disorders 3/18 3/7
Diarrhea 4/18 3/7
Nausea/vomiting 9/19 1/7
Laboratory findings
Thrombocytes at
admission (×109/L)
117 (75–276) 82 (59–111)
Creatinine at
admission
(mg/dL [0.5-1.4])
3.7 (1.7-6.2) 2.5 (1.9-2.9)
Creatinine peak
level (mg/dL
[0.5-1.4])
5.6 (2.9-6.9) 3.1 (2.7-4.5)
CrP at admission
(mg/dL [0.1-0.4])
5.4 (2–6.8) 8.0 (4.6-8.7)
Lactate
dehydrogenase,
serum
285.0 (229–334) 313.0 (376–256)
Clinical signs
Fever 14/18 7/7
Blood pressure
mmHg
Systolic mmHg 150 (140–160) 120 (100–150)
Diastolic mmHg 86 (75–96) 80.0 (72–91)
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In our present study, creatinine peak levels were sig-
nificantly higher in the group with increased lipase levels
compared to the group with normal lipase levels. This
indicates a more severe course of the disease. Therefore,
another possible explanation for elevated lipase levels
in this group of patients could be an enhanced inflam-
matory response caused by a generalized PUUV infec-
tion involving endothelial cells of capillaries within the
pancreas.
Several limitations of the evaluation need to be discussed.
In our cohort of patients, lipase levels were measured at the
physician’s discretion instead of a standardized manner
(certainly in cases of suspected acute pancreatitis), which
leads to a selection bias. Therefore the incidence of subclin-
ical elevation of lipase levels might be higher. Furthermore,
we performed a retrospective non-blinded study of medical
case reports, with all known associated limitations, e.g. it
would be quite helpful to have alternative biomarkers such
as amylase or elastase measured in stool of the patients.
Furthermore, amylase was not determined in our study
population.
Conclusions
This is the first study to investigate the prevalence of
elevated lipase levels and acute pancreatitis and its im-
pact on the clinical course in a large and representa-
tive cohort of patients with acute PUUV-induced NE.
Elevated lipase levels are common in NE and may re-
flect a more severe form of NE. Slightly elevated lipase
levels should no lead to misdiagnose acute NE, but
acute pancreatitis must be considered if enzyme levels
are more than threefold normal in association with
clinical manifestations.
Table 3 Clinical data of 456 patients with PUUV infection, significant p values were marked in bold
Variable Patients in whom lipase
was determined
Patients in whom lipase was
not determined
P
n 166 290 -
Age (years ± SD) 47.4 ± 14.6 48.8 ± 14.6 0.249
Female/male 63/103 102/188 0.613
Onset of symptoms prior to admission to hospital (days) 5.0 (3.6-7.0) 5.0 (3.0-7.0) 0.080
Duration of hospital stay (days) 7.0 (4.0-10.0) 7.0 (5.0-9.0) 0.999
Symptoms
Abdominal pain 67/166 84/290 0.017
Back-/flank pain 119/166 188/290 0.147
Headache 108/166 139/290 0.0004
Visual disorders 41/166 60/290 0.349
Diarrhea 42/166 50/290 0.052
Nausea/vomiting 79/166 136/290 0.923
Laboratory findings
Thrombocytes at admission (×109/L) 105.0 (76.5-174) 128.5 (87.8-213.5) 0.005
Minimum thrombocyte level (×109/L) 96.0 (71.0-163.0) 124 (77.8-212.0) 0.007
Creatinine at admission (mg/dL [0.5-1.4]) 1.8 (1.2-3.6) 1.8 (1.2-3.3) 0.983
Creatinine peak level (mg/dL [0.5-1.4]) 3.0 (1.7-5.2) 2.7 (1.6-4.6) 0.218
CrP at admission (mg/dL [0.1-0.4]) 4.4 (2.8-7.6) 3.9 (2.2-6.8) 0.094
CrP peak level (mg/dL [0.1-0.4]) 5.0 (3.0-8.7) 4.5 (2.8-8.0) 0.340
Lactate dehydrogenase, serum 275.5 (247.0-327.0) 271.5 (240–324.5) 0.705
Clinical signs
Fever 144/166 265/290 0.149
Blood pressure
systolic 130.0 (119.0–146.0) 130.0 (120.0-146.0) 0.788
diastolic 80.0 (70.0–90.0) 80.0 (71.5-89.0) 0.951
Heart rate 77.6 (64.0–88.0) 74.5 (65.0-84.0) 0.148
Abdominal ultrasound 138/166 160/290 <0.0001
Abdominal CT scan 8/166 4/290 0.035
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